Results 271 to 280 of about 38,272 (314)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life.
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly   +2 more sources

Dapagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine, 2020
BACKGROUND Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.
Ricardo C Correa-Rotter, Glenn Chertow, Tom H Greene   +2 more
exaly   +2 more sources

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine, 2019
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of
John J V Mcmurray, Lars Køber, Mikhail N Kosiborod   +2 more
exaly   +2 more sources

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
Itamar Raz, Marc P Bonaca, Ofri Mosenzon
exaly   +2 more sources

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Nature Medicine, 2022
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown.
Pardeep S Jhund, Toru Kondo, Jawad Haider Butt   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dapagliflozin

Reactions Weekly
  +16 more sources

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.

NEJM Evidence
Dapagliflozin in Myocardial InfarctionA total of 4017 patients with acute myocardial infarction, but no diabetes or chronic heart failure, were randomly assigned 10 mg of dapagliflozin or placebo.
Stefan James, D. Erlinge, Robert F Storey, Darren K. McGuire, M. D. de Belder, N. Eriksson, Kasper Andersen, D. Austin, G. Arefalk, D. Carrick, R. Hofmann, S. Hoole, Daniel A Jones, Kelvin Lee, Hans Tygesen, P. A. Johansson, A. Langkilde, W. Ridderstråle, E. Parvaresh Rizi, J. Deanfield, Jonas Oldgren   +20 more
semanticscholar   +1 more source

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.

New England Journal of Medicine
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI)
S. Raposeiras-Roubín, I. Amat-Santos, Xavier Rosselló, Rocío González Ferreiro, I. González Bermúdez, Diego López Otero, L. Nombela‐Franco, L. Gheorghe, J. L. Díez, Carlos Baladrón Zorita, J. Baz, A. J. Muñoz García, V. Vilalta, Soledad Ojeda-Pineda, J. M. de la Torre Hernandez, J. G. Córdoba Soriano, A. Regueiro, Pascual Bordes Siscar, J. Salgado Fernández, B. García Del Blanco, R. Martín-Reyes, Rafael Romaguera, Cesar Moris, S. García Blas, J. Franco-Peláez, I. Cruz-González, D. Arzamendi, N. Romero Rodríguez, F. Díez-del Hoyo, S. C. Camacho Freire, Francisco Bosa Ojeda, J. C. Astorga Burgo, Eduardo Molina Navarro, Juan Caballero Borrego, Valeriano Ruiz Quevedo, Á. Sánchez-Recalde, Vicente Peral Disdier, Eduardo Alegría-Barrero, J. Torres-Llergo, Gisela Feltes, J. F. Fernández Díaz, C. Cuellas, Gustavo Jiménez Brítez, J. Sánchez-Rubio Lezcano, C. Barreiro-Pardal, I. Núñez-Gil, E. Abu-Assi, A. Iñíguez-Romo, Valentín Fuster, Borja Ibáñez   +49 more
semanticscholar   +1 more source

Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial

British medical journal
Objective To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH). Design Multicentre, double blind, randomised, placebo controlled trial.
Jiayang Lin, Yan Huang, Bingyan Xu, X. Gu, Junlin Huang, Jia Sun, Lijing Jia, Jiang He, Chensihan Huang, Xueyun Wei, Jinjun Chen, Xiaomin Chen, Jingping Zhou, Lixian Wu, Peizhen Zhang, Yaxin Zhu, Huimin Xia, Ge Wen, Yating Liu, Shiqun Liu, Yanmei Zeng, Lin Zhou, Hongxia Jia, Hua He, Yao-ming Xue, Fenglin Wu, Huijie Zhang   +26 more
semanticscholar   +1 more source